ArticleRespiratory medicine2021
The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study.
Article in Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Pulmonary Sarcoidosis in Qatar: Clinical Features, Diagnostic Profile and Treatment Patterns in a Multi-Ethnic Population.The clinical respiratory journal · 2026Observational
- Quality of Life in Sarcoidosis.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.The Lancet. Respiratory medicine · 2026Review
- Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.Frontiers in medicine · 2026Review
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- Pulmonary Tuberculosis and Sarcoidosis Presented With Pleuropericardial Effusion: A Challenging Case Report.Case reports in infectious diseases · 2026Article
- Differential Transcriptomic Features of Peripheral Blood Mononuclear Cells in Pulmonary Sarcoidosis with and Without Extrapulmonary Lesions in an East Asian Population.Biomedicines · 2025Article
- Exploring gender and ethnic disparities in sarcoidosis: insights from the British Thoracic Society UK Interstitial Lung Disease Registry.BMJ open respiratory research · 2025Article
- Article
- Microbiome Against the Background of the Complex Aetiology in Sarcoidosis-What Do We Already Know?Life (Basel, Switzerland) · 2025Review
- Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium.Circulation. Arrhythmia and electrophysiology · 2025Observational
- Mind the Gap: Racial Disparities in Sarcoidosis Diagnostic Delays.CHEST pulmonary · 2025Article
- First insights and future research perspectives from the sarcoidosis registry at the Medical University of Vienna.Scientific reports · 2025Article
- Article
- The textures of sarcoidosis: quantifying lung disease through variograms.Physics in medicine and biology · 2025Article
- Clinical characteristics of patients with pulmonary sarcoidosis treated with systemic steroids in Japan.Frontiers in medicine · 2025Article
- Big data in sarcoidosis.Current opinion in pulmonary medicine · 2024Review
- Association of Area Deprivation Index with Adherence to Proposed Regimen in Patients with Sarcoidosis in Detroit, Michigan.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 15 institutions in 10 countries.
Funding
Abstract
objectiveTo study how demographic differences impact disease manifestation of sarcoidosis using the WASOG tool in a large multicentric study.
methodsClinical data regarding 1445 patients with sarcoidosis from 14 clinical sites in 10 countries were prospectively reviewed from Feb 1, 2020 to Sep 30, 2020. Organ involvement was evaluated for the whole group and for subgroups differentiated by sex, race, and age.
resultsThe median age of the patients at diagnosis was 46 years old; 60.8% of the patients were female. The most commonly involved organ was lung (96%), followed by skin (24%) and eye (22%). Black patients had more multiple organ involvement than White patients (OR = 3.227, 95% CI: 2.243-4.643) and females had more multiple organ involvement than males (OR = 1.238, 95% CI: 1.083-1.415). Black patients had more frequent involvement of neurologic, skin, eye, extra thoracic lymph node, liver and spleen than White and Asian patients. Women were more likely to have eye (OR = 1.522, 95%CI: 1.259-1.838) or skin involvement (OR = 1.369, 95%CI: 1.152-1.628). Men were more likely to have cardiac involvement (OR = 1.326, 95%CI: 1.096-1.605). A total of 262 (18.1%) patients did not receive systemic treatment for sarcoidosis. Therapy was more common in Black patients than in other races.
conclusionThe initial presentation and treatment of sarcoidosis was related to sex, race, and age. Black and female individuals are found to have multiple organ involvement more frequently. Age at diagnosis<45, Black patients and multiple organ involvement were independent predictors of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.